OX
OXBOF.US Oxford BioDynamics Plc
- Market cap
- USD 40.3M
- P/E
- -
- P/B
- 9.34x
- ROE
- -549.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is OXBOF.US undervalued?
Graham numberThe Graham number of Oxford BioDynamics Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oxford BioDynamics Plc fundamental analysis
No fundamental analysis for Oxford BioDynamics Plc yet.
Oxford BioDynamics Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oxford BioDynamics Plc
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screenin…
Full company profileOxford BioDynamics Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oxford BioDynamics Plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.09M | 1.18M | 1.19M | 907K | 456K | 341K | 154K | 510K | 636K | 1.10M | 2.76M |
| Gross Profit | 575K | 776K | 493K | 439K | -166K | 341K | 116K | 266K | 289K | 522K | -970K |
| Operating Income | -2.33M | -4.00M | -2.60M | -3.72M | -4.95M | -7.51M | -8.60M | -10.2M | -12.9M | -11.1M | -18.9M |
| EBITDA | -1.91M | -3.79M | -2.09M | -3.00M | -4.46M | -6.43M | -6.16M | -9.84M | -10.3M | -9.80M | -16.6M |
| Net Income | -1.73M | -3.80M | -1.95M | -2.80M | -4.31M | -6.68M | -6.71M | -10.8M | -11.6M | -11.2M | -17.9M |
| EPS | -0.02 | -0.04 | -0.02 | -0.03 | -0.05 | -0.07 | -0.07 | -0.07 | -0.05 | -0.01 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 9.02M | 12.7M | 20.9M | 18.8M | 15.4M | 15.4M | 11.3M | 16.1M | 12.1M | 8.09M | 9.11M |
| Total Liabilities | 1.28M | 1.08M | 892K | 1.20M | 1.77M | 8.69M | 8.76M | 10.1M | 7.75M | 6.97M | 5.85M |
| Shareholders' Equity | 7.72M | 11.6M | 20.0M | 17.6M | 13.6M | 6.68M | 2.59M | 6.06M | 4.36M | 1.12M | 3.26M |
| Cash & Short-term Investments | 7.28M | 10.8M | 18.3M | 15.5M | 11.5M | 4.34M | 999K | 5.25M | 2.83M | 1.39M | 2.52M |
| Total Debt | - | - | - | - | 541K | 6.59M | 6.14M | 6.44M | 5.74M | 5.11M | 4.29M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.35M | -1.53M | -1.94M | -2.27M | -3.40M | -5.92M | -5.18M | -8.29M | -10.2M | -10.4M | -18.1M |
| Capital Expenditure | 208K | 425K | 776K | 632K | 457K | 3.09M | 901K | 716K | 595K | 244K | 28.1K |
| Free Cash Flow | -1.56M | -1.95M | -2.72M | -2.90M | -3.86M | -9.01M | -6.08M | -9.01M | -10.8M | -7.82M | -18.1M |
| Ratios | |||||||||||
| ROE | -22.4% | -32.9% | -9.8% | -15.9% | -31.8% | -100.1% | -259.3% | -178.8% | -265.4% | -999.4% | -549.1% |
| ROA | -19.2% | -30.0% | -9.3% | -14.9% | -28.1% | -43.4% | -59.2% | -67.1% | -95.5% | -137.9% | -196.4% |
| Net Profit Margin | -158.6% | -321.6% | -164.7% | -308.7% | -945.8% | -1,959.5% | -4,357.1% | -2,122.7% | -1,818.7% | -1,018.5% | -649.8% |
| Debt to Equity | - | - | - | - | 0.04x | 0.99x | 2.37x | 1.06x | 1.32x | 4.58x | 1.32x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oxford BioDynamics Plc dividends
Oxford BioDynamics Plc has not paid dividends in the last 9 fiscal years.
Who owns Oxford BioDynamics Plc
- Insiders 12.12%
- Institutions 39.17%
- Public & others 48.72%
- Shares outstanding 13.4B
- Free float 3.27B
Oxford BioDynamics Plc company profile
- Company name
- Oxford BioDynamics Plc
- Ticker
- OXBOF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Fiscal year end
- September
- Address
- 3140 Rowan Place, Oxford, United Kingdom, OX4 2WB
- Phone
- 44 1865 518 910
- Website
- oxfordbiodynamics.com
About Oxford BioDynamics Plc
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch Orion, a cloud platform, running on google cloud architecture; and EpiSwitch Explorer Array Kit platform, enabling advanced analysis of 3D regulatory control points. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Oxford BioDynamics Plc management
6- Mr. Paul Leslie Stockdale F.C.A., M.A.CFO & Executive Director · born 1975
- Dr. Alexandre Akoulitchev M.A., Ma (Oxon), Ph.D.Chief Scientific Officer & Executive Director · born 1962
- Mr. Richard Alan ComptonCEO & Executive Director · born 1969
- David BlumPresident
- Dr. Ewan Hunter B.Sc., Ph.D., Ph.D., (KCL)Chief Data Officer
- T. DemainCompany Secretary